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ABSTRACT 22	  
Canine Angiostrongylosis (CA), a gastropod-borne parasitic infection caused by the 23	  
metastrongyloid nematode Angiostrongylus vasorum, is an important cause of significant 24	  
morbidity to domestic dogs across the UK	  as well as in other European countries. This study 25	  
aimed to ascertain the frequency at which particular drugs were used by primary care 26	  
practitioners in the UK for therapy against and prophylaxis for CA. Primary care veterinary 27	  
clinicians were surveyed using an online questionnaire and face-to-face or telephone 28	  
interviews. Eighty-six veterinary surgeons responded. The majority of practices (n = 52) 29	  
included lungworm in their standard anthelmintic protocols; moxidectin was the most 30	  
common drug used for prophylaxis (n = 71). Fenbendazole was the most frequently selected 31	  
drug, by 45% of vets, for treatment of confirmed cases of CA despite it being unlicensed for 32	  
this purpose in the UK and the absence of a clear treatment protocol. The results of this pilot 33	  
study provide an initial insight into the approach taken by primary care practitioners in their 34	  
approach to CA.  This provides an important starting point for future studies investigating the 35	  
decision-making for CA amongst UK veterinary surgeons, particularly to clarify whether in a 36	  
larger cohort an unlicensed drug remains the treatment of choice. The absence of a clear 37	  
protocol for fenbendazole means that treatment of dogs affected by CA may be suboptimal, 38	  
increasing the risk of morbidity and mortality.   39	  
 40	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1. Introduction 51	  
Canine angiostrongylosis (CA) is a parasitic disease caused by the cardiorespiratory 52	  
nematode Angiostrongylus vasorum (Superfamily: Metastrongyloidea). Dogs become 53	  
infected after ingesting the third larval stage (L3), usually within an intermediate gastropod 54	  
host or a paratenic host, such as the common frog (Rana temporaria) (Bolt et al., 1993) and 55	  
chicken (Gallus gallus domesticus) (Mozzer and Lima, 2015). In addition, experimental 56	  
infection of Biomphalaria glabrata demonstrated that infected snails shed L3 into the 57	  
environment, which could create a potential free-living reservoir of infection (Barçante et al., 58	  
2003). Rising numbers of confirmed cases of CA have thrown A. vasorum into the spotlight 59	  
globally, driving research into its epidemiology, diagnosis and risk factors (Bwangamoi, 60	  
1972; Helm et al., 2010; Kistler et al., 2014; Penagos-Tabares et al., 2018). It is well-61	  
established that A. vasorum has spread from its original hot spot in South West (Simpson and 62	  
Neal, 1982) and South East England (Chapman et al., 2004) and is now found throughout the 63	  
UK. Cases have been reported as far north as Scotland (Helm et al., 2009); this expanding 64	  
parasite’s territory has probably expanded faster than our knowledge of its pathogenicity and 65	  
epidemiology. The full spectrum of the factors related to increasing prevalence of A. vasorum 66	  
in dogs in Great Britain remains unexplained. However, a study conducted in the fox 67	  
populations showed that the increased prevalence and geographic spread of A. vasorum in 68	  
this reservoir host may have contributed to the increased risk of infection in dogs (Taylor et 69	  
al., 2015). 70	  
CA presents with variable clinical signs and in some cases the infection may be entirely 71	  
sub-clinical. The most common presenting signs relate to the respiratory tract and include 72	  
dyspnoea and coughing. Other clinical signs include pulmonary hypertension, primary and 73	  
secondary disorders of haemostasis (with associated haemorrhage) and neurological signs, 74	  
including seizures. This is a disease with a myriad of possible presentations and therefore 75	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remains a diagnostic challenge for veterinarians (Chapman et al., 2004; Koch and Willesen, 76	  
2009). The lack of a clear pathognomonic profile and the non-specific clinical signs may 77	  
delay anthelmintic treatment while another suspected cause is investigated, resulting in more 78	  
severe pathology. This is particularly the case for dogs presenting with coagulopathies or 79	  
neurological signs in the absence of obvious respiratory signs. A major concern with CA is 80	  
that it may remain largely asymptomatic and can manifest as sudden death (Bourque et al., 81	  
2002; Brennan et al., 2004).  82	  
 In the UK, a number of macrocyclic lactone-based products are licensed to treat 83	  
angiostrongylosis, containing moxidectin in a topical form (along with imidacloprid) or 84	  
milbemycin oxime in tablet form. The treatment efficacy for a single dose of the formulation 85	  
of imidacloprid/moxidectin was found to be 85.2%. There was no significant difference 86	  
between this and the 91.3% efficacy of fenbendazole administered daily for 20 days. The 87	  
former of these  treatment being licensed for use against AV in dogs, whereas the latter is not. 88	  
Of those dogs still shedding larvae which received a further dose of imidacloprid/moxidectin, 89	  
all were then found to be Baermann negative (Willesen et al., 2007).  90	  
Besides being licensed for treatment of adult worms imidacloprid/moxidectin is licensed 91	  
for monthly use for the prevention of angiostrongylosis and prevention of patent infection, 92	  
with 100% efficacy against L4 larvae and immature adults (L5) of A. vasorum (Schnyder M. 93	  
et al., 2009). In regards to milbemycin oxime, commonly available in combination with 94	  
praziquantel, a two-dose protocol achieved a clinical improvement, but without clearance of 95	  
larval shedding and treatment was therefore extended to a protocol of using 4 weekly 96	  
treatments to reduce the level of infection, achieving negative faecal Baermann results in 14 97	  
out of 16 dogs (Conboy, 2004). Monthly use of milbemycin oxime is licensed for prevention 98	  
of angiostrongylosis by reduction in the level of infection by immature adult (L5) and adult 99	  
parasite stages, with a recent study showing a worm count reduction efficacy of 94.9% 100	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(Lebon et al., 2016). Whilst there are additional publications testifying the efficacy of 101	  
fenbendazole in naturally occurring CA infections (Brennan et al., 2004; Chapman et al., 102	  
2004; Manning, 2007), in the absence of licensing, optimal dose, frequency and duration 103	  
remain unclear. The risks of using unlicensed products are highlighted by levamisole, which 104	  
was historically advocated for the treatment of CA due to its potency and rapid onset of 105	  
action. However despite efficacy against CA, this is no longer recommended due to the 106	  
occurrence of significant side-effects including anaphylaxis in levamisole-treated patients, 107	  
thought to result at least in part from the rapid increase in circulating worm antigen (Søland 108	  
and Bolt, 1996).  109	  
The efficacies of many of these drugs have been studied experimentally and in a number 110	  
of clinical studies, and they have been licensed as a result. It is at present however unknown 111	  
which products primary care veterinary surgeons in the UK are choosing to treat CA. It is 112	  
suspected anecdotally that fenbendazole, whilst unlicensed remains the first-choice 113	  
anthelminthic treatment for most primary care vets. In addition to this, it also remains 114	  
unknown as to their choice of prophylaxis. A review of the therapeutic choices made by 115	  
veterinary surgeons around CA treatment and prophylaxis across the UK is therefore 116	  
important. In addition, the reasons behind these choices and the ‘perceived’ efficacy of this 117	  
choice made by primary care clinicians are also of value. Whilst the latter point is difficult to 118	  
prove retrospectively, the vet’s opinion is important as this will influence their future 119	  
therapeutic choices. Perhaps a more important rationale for this study in the UK is the 120	  
importance of prescribing veterinary medication according to the cascade. Therefore, the 121	  
aims of this pilot survey were to identify which anthelmintic drugs were being used for 122	  
therapy and prophylaxis of CA by UK primary care veterinary surgeons. An additional aim 123	  
was to review the reported clinical signs in the confirmed cases of CA along with the method 124	  
by which the disease was confirmed. Finally, the clinical outcome of cases diagnosed with 125	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CA and the perspective of the veterinary surgeons on the efficacy of drugs used in the 126	  
treatment was also examined.  127	  
 128	  
2. Material and methods 129	  
 130	  
2.1. Ethics statement 131	  
The Institutional ethical review committee approved this study. Responses to the survey were 132	  
entirely voluntary and all data obtained was anonymised and stored securely.  133	  
 134	  
2.2. Data collection 135	  
Data were collected for this study using a combination of an online questionnaire (Table 1), 136	  
and telephone or face-to-face interviews, all targeting small animal veterinary surgeons in 137	  
primary care practice. The online survey contained 4 sections, beginning with a demographic 138	  
question asking for the number of years the clinician had been working in small animal 139	  
practice (SAP). This was followed by questions on the drugs used to prevent CA (clinicians 140	  
could indicate more than one), and whether the practice’s standard worming prophylaxis was 141	  
licensed for lungworm prevention. The final section was focused on treatment of CA, asking 142	  
the clinician for the drug they used and their efficacy rating for this drug. For ease of 143	  
comparison, drugs were listed according to their classification and not trade name for ease of 144	  
understanding. Clinicians were allowed to indicate more than one drug. The survey provided 145	  
an optional ‘other’ field which contained drugs less frequently mentioned (ivermectin and 146	  
selamectin). The online questionnaire was piloted by using other primary care veterinary 147	  
surgeons and changes were implemented where required. The questionnaire was available for 148	  
completion by veterinary surgeons during the pilot project period: between 11/10/2016 and 149	  
28/10/2016 via a specific URL provided to 287 primary care practices throughout England. 150	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Additional interviews were conducted to supplement the online questionnaire, using the same 151	  
questions and additionally requesting the standard worming protocol of the practice, then 152	  
determining if the product was licensed in the UK to prevent CA. Eleven interviews were 153	  
conducted in-person and 28 (of 59 practices contacted) consented to a telephone interview. 154	  
Direct interviews were conducted across Greater Manchester, Lancashire, Leicestershire, 155	  
Nottinghamshire and Norfolk. This produced a distribution of 326 practices (287 via email, 156	  
28 via telephone and 11 via direct interview). 157	  
 158	  
2.3. Data analysis 159	  
Responses to the online survey and interview locations were plotted on a map of England in 160	  
order to assess geographical coverage. Data from all response types was collected, 161	  
categorized and analysed using Excel 2016 (Microsoft Corporation©) and SPSS Version 23 162	  
2005 (IBM®). Maps were created using the mapping feature of Excel 2016 (Microsoft 163	  
Corporation©). 164	  
 165	  
3. Results 166	  
 167	  
3.1. Participants and distribution 168	  
Eighty-six responses were obtained from the 326 practices contacted representing a 26% 169	  
response rate. The online questionnaire provided 47 responses (representing 14% of total 170	  
distribution), 28 were from the telephone interviews (8.6% of total) and 11 from face-to-face 171	  
interviews (3.4% of total). In order to assess how demographics of the participants influenced 172	  
their responses, the number of years’ post-qualification that the veterinary surgeons had been 173	  
in SAP was collated into a histogram (Fig. 1). The spread of all responses by county is shown 174	  
in Fig. 2A. Greater London provided the greatest number of responses (13), followed by 175	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Bristol (5) and then Cornwall, Norfolk, Nottinghamshire and Warwickshire (all of which 176	  
provided 4). An additional map was created, displaying the number of confirmed cases of CA 177	  
varying by county (Fig. 2B). Of the 86 responding practices, 19 (22%) stated that one or 178	  
more confirmed cases of CA had been examined at that practice within the previous year. 179	  
When the respondents were asked for the exact number of cases examined, the total came to 180	  
41 across all practices. The maximum number of cases examined at any one practice was 10 181	  
with a median of 2 cases per practice (IQR 1-2). 182	  
  183	  
3.2. Frequency of clinical signs 184	  
A variety of clinical signs were reported by the study participants, those associated with the 185	  
haematologic, respiratory and neurological systems were the most commonly reported (Table 186	  
2). One case was excluded from this analysis due to the fact CA was only discovered at 187	  
referral and the primary care clinician completing the survey was unaware of the presenting 188	  
clinical signs. Three respondents (handling 14 serologically confirmed cases of CA between 189	  
them) observed subclinical cases and another three (6 confirmed cases in total) witnessed the 190	  
sudden death of infected dogs. Signs relating to the gastrointestinal system were noted 191	  
infrequently (one case reporting vomiting and one diarrhoea).    192	  
 193	  
3.3 Diagnostic testing 194	  
Clinicians were asked to select the method(s) they had used to confirm a suspected case of 195	  
CA from the options of: coproscopic examination (sub-options: Baermann, faecal smear), 196	  
cytological diagnosis by bronchoalveolar lavage (BAL), in-house serological assay (Angio 197	  
Detect™), external laboratory ELISA and other (Fig. 3). Two clinicians reported that they 198	  
were unaware of the diagnostic test used for diagnosis. Over 50% of the veterinary surgeons 199	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reported using the Angio Detect™ (IDEXX Laboratories, Wetherby, West Yorkshire, UK) to 200	  
confirm their diagnosis of CA whilst none sent serum samples to an external laboratory for 201	  
ELISA diagnosis. Of the 13 clinicians who used the Angio Detect™ test, three did so in 202	  
conjunction with another testing modality. One respondent used a combination of BAL and 203	  
PCR. 204	  
 205	  
3.4. Treatment of CA 206	  
The treatment choices for confirmed cases of CA by those clinicians surveyed are presented 207	  
in Fig. 4A. There were 51 responses to this question, 17 of which related to treatment given 208	  
in a confirmed case with 34 relating to which drug the clinician would select, were they to 209	  
encounter a case of CA. In the 17 confirmed cases, 45.5% of clinicians selected 210	  
fenbendazole, which was the most popular drug used. Moxidectin and milbemycin oxime 211	  
were each selected by 27.3% of responding clinicians. No other drugs were recommended as 212	  
treatment for CA. In contrast, when asked which drug the clinician would use in a 213	  
hypothetical case of CA, the most frequent response was moxidectin (41%), followed by 214	  
fenbendazole (28%) and milbemycin oxime (23%). 215	  
There were a variety of treatment protocols for CA reported by the responding clinicians. 216	  
The most consistent was monthly moxidectin, with 19/22 (86%) of respondents advising this 217	  
was given to treat CA. Four respondents using milbemycin oxime to treat cases of CA 218	  
advised that this should be given weekly for 4 weeks, one respondent prescribed this weekly 219	  
for 2 weeks and one recommended a single dose to be sufficient for treatment. The remaining 220	  
9 respondents selecting milbemycin oxime to treat CA did not specify the frequency or 221	  
duration of treatment. The dosing schedule reported by 43% of the respondents for 222	  
fenbendazole was once daily. However, there was considerable discrepancy in duration of 223	  
therapy. One clinician reported 3 days, one recommended 5 days, three recommended 7 days, 224	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two recommended 10 days and two recommended 14 days. Unfortunately, 12 clinicians using 225	  
fenbendazole therapy failed to provide a therapeutic frequency or duration. We asked the 19 226	  
clinicians reporting confirmed cases of CA to describe response to therapy. Interestingly, 227	  
only 4 clinicians reported that they re-tested dogs after therapeutic intervention, 228	  
corresponding to 6 of the 41 (15%) infected dogs. Of these six re-tested dogs, all produced 229	  
negative results using the in-house serological assay (Angio Detect™).  230	  
 231	  
3.5. Prevention of CA 232	  
When asked the clinicians if their practice’s standard prophylactic de-worming protocol 233	  
included lungworm prevention, 52 agreed and 28 disagreed. Six respondents reported using 234	  
more than one standard protocol, depending on the dog’s ‘risk of infection’. Surveyed 235	  
clinicians provided information on which drugs were most frequently used as prophylaxis 236	  
against CA. Fig. 4B displays the frequency of drugs being selected as prevention for CA. 237	  
Those respondents that included lungworm prevention in their standard protocol were then 238	  
asked which product was chosen to a achieve this (more than one product could be selected). 239	  
Products containing moxidectin and milbemycin oxime were the most commonly prescribed 240	  
preventatives, with 71 clinicians selecting moxidectin and 56 selecting milbemycin oxime. 241	  
One respondent selected fenbendazole as their prophylactic treatment of choice and two 242	  
selected selamectin. 243	  
 244	  
4. Discussion 245	  
This pilot study was conducted to begin to understand more about how anthelmintics are used 246	  
for treatment of and prophylaxis against CA by primary care clinicians in the UK. The survey 247	  
responses provided a reasonable spread across the UK and there was a reasonable response 248	  
rate of 26%. Despite the reasonable response rate, the absolute number of responses was low 249	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which represents a limitation. This is likely to reflect the short period of data collection, 250	  
which was necessitated due to the timescale over which this pilot study was conducted. There 251	  
was a predominance of responses from those vets with fewer years in small animal practice. 252	  
It is difficult to know whether this reflects that newer graduates are more likely to respond to 253	  
questionnaires perhaps because they did not anticipate compensation or monetary incentives 254	  
for the time spent completing the survey or because newer and updated knowledge about 255	  
diseases and treatments have become available in recent years. Also, young veterinarians, 256	  
aged between 26-35, represent a third of veterinary surgeons in the UK according to the 2014 257	  
RCVS survey (Buzzeo et al., 2014); thus it is feasible to expect younger vets to represent a 258	  
large proportion of the respondents. The highest correlation between the number of responses 259	  
and the frequency of detection of clinical cases has been detected in Greater London, which is 260	  
in agreement with others (Kirk et al., 2014). This correlation might be due to previous 261	  
knowledge and experience in CA therapeutics in clinics in this geographic area, which had 262	  
prolonged history of receiving cases of CA than those in the low endemic areas. However, 263	  
the small sample size limits the generalization of our finding and does not allow a robust 264	  
correlation between the participant responses to the questionnaire and the spatial distribution 265	  
and intensity of clinical A. vasorum cases seen in dogs in England to be made. How this 266	  
correlation may differ with age of the clinicians remains to be determined. 267	  
Under the veterinary prescribing cascade in the UK, clinicians must first use a drug that 268	  
is licensed to treat the condition in question (in this case CA) in the patient’s species (in this 269	  
case dogs) before moving onto alternatives in justifiable circumstances (VMD, 2015). 270	  
Therefore, a clinician’s first choice of treatment for CA should theoretically contain either 271	  
moxidectin or milbemycin oxime. The results obtained here suggest that the majority of 272	  
clinicians are using fenbendazole to treat CA, which is off license and does not follow the 273	  
cascade. The reasons behind this were not interrogated in this pilot study, but a subsequent 274	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study is planned to understand more about what drives decision-making for treatment of CA. 275	  
It is possible that the first-line use of fenbendazole is as a result of its long-standing presence 276	  
in the market place, suggesting veterinary surgeons feel more familiar with the outcome for 277	  
CA cases. That said, the majority of our responses came from relatively recent graduates and 278	  
not from clinicians that had been in the profession for a considerable time period. Moxidectin 279	  
became available in April 2003, shortly followed by milbemycin oxime tablets, compared to 280	  
fenbendazole which was first produced in January 1993 (VMD, 2017). This clearly warrants 281	  
further investigation to provide important insight into understanding decision-making around 282	  
this condition. This is important, as at least from this pilot study, the licensed products are 283	  
less frequently used than the unlicensed one, despite the advice of the RCVS and the VMD.  284	  
In trying to seek some consensus as to the treatment strategies employed by the cohort of 285	  
clinicians surveyed, it seems that selected fenbendazole is being used for differing periods of 286	  
time. Periods ranged from 3 to 14 days. The literature would suggest that fenbendazole may 287	  
be effective in treating CA with courses lasting between 5 and 21 days (Chapman et al., 2004; 288	  
Willesen et al., 2007). There was no association between those vets using fenbendazole for a 289	  
shorter period and ineffective therapy or relapse. Further research is necessary to clarify the 290	  
most appropriate duration of therapy required to obtain maximum efficacy of fenbendazole. 291	  
Whilst all drugs, fenbendazole, moxidectin and milbemycin oxime (Conboy, 2004; 292	  
Willesen et al., 2007), have been demonstrated to be efficacious, Moxidectin was found to be 293	  
the most frequently prescribed drug in hypothetical cases of CA. The reasoning behind this is 294	  
currently unclear but may be because it only requires a single application or that it doesn’t 295	  
rely on having to tablet the dog. Milbemycin oxime was the least frequently prescribed drug 296	  
(excluding ivermectin and selamectin, categorised into the field entitled “other”) in a 297	  
hypothetical case. This could be due to a perceived low efficacy, the fact that it comes in 298	  
tablet form, the need for multiple doses or another reason. Another study into the treatment 299	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efficacy of milbemycin oxime to ascertain the minimum number of weeks treatment needed, 300	  
would benefit clinicians.  301	  
The low number of treated cases that are re-tested at a later date could be influenced by a 302	  
host of factors, such as the cost of such testing, perceived hassle or possible fatality. Whilst 303	  
there are many reasons clinicians may avoid re-testing patients, it must be remembered that 304	  
without this information it cannot be concluded as to whether the apparent improvement in 305	  
clinical signs was associated with true resolution of infection. It is important to reiterate that 306	  
the eradication of the infection means that there is no residual worm burden that could lead to 307	  
recrudescence. Treatment of CA does not result in lasting immunity and as such treated dogs 308	  
(even those that re-test negative) should continue to receive a monthly anthelmintic for 309	  
preventative purposes (Böhm et al., 2014; Lebon et al., 2016; Schnyder et al., 2009).  310	  
This study found that, moxidectin and milbemycin oxime were the most frequently 311	  
prescribed preventative drugs, reflecting their general popularity in primary practice. 312	  
Alternatively, this may represent an attempt to include lungworm prevention in the standard 313	  
de-worming protocol of a practice, without the need to use an additional drug. In this small 314	  
survey, moxidectin was more frequently prescribed than milbemycin oxime. Whether this is 315	  
owing to its higher efficacy or simply its existing popularity in veterinary practice is unclear. 316	  
The majority of clinicians responded yes when asked if their practice’s standard de-worming 317	  
protocol included lungworm prophylaxis. Whilst important that 65% of the surveyed 318	  
practices are including prophylaxis for CA, this means that 35% of practices do not. This may 319	  
relate to a perceived lower prevalence in their area, however it is now widely accepted that A. 320	  
vasorum is spreading throughout the UK implying that no area can be guaranteed as 321	  
lungworm-free (Kirk et al., 2014). Some clinicians may wish to adopt a risk-based approach 322	  
to CA prevention in areas where the parasite is not endemic. Assessing the relative risk is one 323	  
way that this could be carried out. The risk factors include: age (dogs less than 18 months old 324	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were most likely to test positive), no CA prophylaxis for the past 3 months and possibly 325	  
season (dogs were more likely to test positive in winter and spring) (Morgan et al., 2010). It 326	  
must be mentioned here that the online respondents were directly asked if their standard de-327	  
worming protocol included lungworm prevention and not to provide details of this protocol. 328	  
This creates the possibility that these clinicians may in fact not be using effective CA 329	  
prophylaxis however given the nature of the study, the protocol could not be determined from 330	  
the responses.   331	  
A secondary aim of this survey was to look at the range of clinical signs associated with 332	  
CA, encountered in primary care practice. Morgan et al. (2010) found the 3 most common 333	  
clinical signs to be coughing, dyspnoea and lethargy respectively. This pilot study identified 334	  
coughing, haemorrhage and depression as the most frequently reported signs. These are 335	  
therefore very similar in as much as the interpretation of lethargy and depression could be 336	  
considered variations on the same presenting sign associated with the neurological system. 337	  
An important highlight from this study is that CA may be an incidental finding and therefore 338	  
particular presenting clinical signs may not be associated with the infection per se, but the 339	  
result of an unconnected comorbidity. Although respiratory signs and coagulopathy are well-340	  
accepted presenting signs association with CA, vomiting/diarrhoea have been less frequently 341	  
reported to be significant findings in previous studies (Chapman et al., 2004; Koch and 342	  
Willesen, 2009; van Doorn et al., 2009). The single episodes of vomiting and diarrhoea 343	  
occurring in this pilot study are unlikely to be directly related to CA. As expected, the 344	  
preferred diagnostic approach to confirm a suspected case of CA was the Angio Detect™ 345	  
test. Whilst the specific reasons for this were not surveyed, it is perhaps due to its simplicity, 346	  
reliability and rapidity of results (Liu et al., 2017). Despite a specificity of 100%, it must be 347	  
remembered that with a sensitivity of 84.6% (lower than the commercially available CA 348	  
ELISA 94.9%) it is less suited as a screening test (Schnyder et al., 2014). Therefore given the 349	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potential for a false negative result with Angio Detect™, it is important that additional 350	  
diagnostics are employed to effectively rule out CA when it is a major differential. 351	  
 352	  
5. Conclusion 353	  
Responding clinicians indicated that they would be likely to use moxidectin to treat a 354	  
hypothetical case of CA, however contrary to this, the most commonly prescribed drug in 355	  
confirmed cases of CA was actually fenbendazole. It is therefore unclear as to what 356	  
influences UK veterinary surgeon’s choice of drug for CA, particularly when fenbendazole is 357	  
unlicensed. From this small pilot study and in line with the literature on CA regarding the 358	  
optimal duration and dose of fenbendazole, there appeared to be no consensus amongst the 359	  
vets as to the optimal duration and dose of therapy for fenbendazole. This study highlights the 360	  
need for larger and more detailed studies in to the choices that veterinary surgeons in the UK 361	  
are making in relation to CA. Once these have been completed the reasons for particular 362	  
therapeutic choices can be better understood. 363	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Figure legends: 461	  
 462	  
	  463	  
	  464	  
Fig. 1. A histogram displaying the frequency of responses from different brackets of years in 465	  
SAP. The slight left skew in the curve indicates that more survey responses were obtained 466	  
from clinicians who had spent less time working in SAP, whereas those with more years in 467	  
SAP were less represented. 468	  
 469	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Fig. 2. Mapping the distribution of the survey respondents and clinical cases of CA in 501	  
England. (A) Geographical distribution of responses to the survey by county. A relatively 502	  
even coverage of England was achieved with Greater London providing the highest number 503	  
of total responses.	  Shading intensity reflects the number of responses – darker reflects more 504	  
responses.  (B) Geographical distribution of CA cases reported by the responding clinicians. 505	  
Confirmed cases were reported in Bristol (3), Buckinghamshire (1), Cumbria (1), Essex (1), 506	  
Greater London (9), Greater Manchester (4), Kent (2), Merseyside (4), Nottinghamshire (3), 507	  
Surrey (2) and Warwickshire (12). 508	  
23	  
	  
 509	  
 510	  
Fig. 3. The method(s) used by primary care clinicians to diagnose CA. The numbers at the 511	  
outer edge of the chart represent the percentage of clinicians using that diagnostic test. 512	  
Coproscopic examination consisted of: Baermann test, faecal smear or unspecified, and 513	  
clinicians could select more than one. The most frequently used test was Angio Detect™ 514	  
while none of the surveyed clinicians used the external ELISA.  515	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  530	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Fig. 4. (A) The percentage of clinicians selecting the drugs to treat both confirmed and 532	  
hypothetical cases of CA. Although the most frequently selected drug in a hypothetical case 533	  
was moxidectin, fenbendazole was the most commonly used drug in confirmed cases. Other 534	  
responses include selamectin (selected by 2 clinicians) and ivermectin (selected by 1 535	  
clinician). (B) The most frequently used drugs for the prevention of CA. Moxidectin was the 536	  
most commonly advised preventative drug, with milbemycin oxime second. Two clinicians 537	  
recommended selamectin and only one advised fenbendazole. 538	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Table 1 539	  
Questions completed by clinicians who took part in the online survey.  540	  
Category       Question 
Demographic -   Please provide your practice’s post code 
-   How many years have you worked in SAP? 
Prophylaxis -   Which de-worming product(s) do you recommend for the 
prevention of A. vasorum infection and at what dose/frequency? 
 -   To your knowledge, how many times has a dog become 
infected with A. vasorum whilst using this prevention protocol? 
 -   Does your practice’s standard de-worming protocol include 
lungworm prevention? 
Cases -   Have you seen a confirmed case of angiostrongylosis at your 
practice within the last year (if yes, please indicate how many 
cases)? 
 -   Which of the following symptoms were exhibited by the 
patient(s)? * 
 -   By what method was the diagnosis of angiostrongylosis 
confirmed? * 
Treatment  -   Which de-worming product(s) have you used in the past to treat 
a confirmed case of angiostrongylosis and at what 
dose/frequency? 
 -   How would you rate the efficacy of this treatment? 
 -   If the treatment was successful, after what period of time was 
the patient considered to be cured of infection? 
26	  
	  
 -   How many of the treated dogs were re-tested at a later date? 
 -   Of these re-tested dogs, how many displayed a positive result? 
 541	  
*For these questions, clinicians could select multiple options from lists on the screen, or add 542	  
their own choice. 543	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Table 2 570	  
The frequency of clinical signs relating to CA. Clinical signs reported by responding 571	  
clinicians associated with confirmed cases of CA categorised into those presenting with 572	  
single or multiple clinical signs. Coughing, haemorrhage and depression were the most 573	  
commonly reported signs. 574	  
 575	  
*One respondent (2 confirmed cases) failed to specify which clinical signs had been 576	  
displayed as CA was discovered at referral. 577	  
 578	  
 579	  
 580	  
 581	  
Clinical presentation Clinical signs (number of confirmed cases) 
Individual signs Coughing (2) 
 Dyspnoea (1) 
 Haemorrhage (1) 
 Total number of cases = 4 
Combined signs Coughing, exercise intolerance, haemorrhage (3) 
 Coughing, haemorrhage, sudden death (3) 
 Dyspnoea, coughing, exercise intolerance (2) 
 Dyspnoea, coughing, depression, haemorrhage, sudden death (2) 
 Depression, haemorrhage (2) 
 Coughing, depression, haemorrhage (2) 
 Depression, haemorrhage, vomiting, neurological deficits (2) 
 Coughing, haemorrhage (1) 
 Dyspnoea, coughing, depression (1) 
 Depression, exercise intolerance, diarrhoea (1) 
 Dyspnoea, haemorrhage, sudden death (1) 
 Dyspnoea, coughing, depression, exercise intolerance (1) 
 Coughing, asymptomatic (10) 
 Haemorrhage, asymptomatic (2) 
 Total number of cases = 33 
Asymptomatic No clinical signs (2) 
 Total number of cases = 2 
Unspecified* Unknown (2) 
 Total number of cases = 2  
